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ABSTRACT

Prostate cancer (PCa) is an incredibly common disease in the United States, with
approximately 170,000 new diagnoses and 30,000 deaths occurring on an annual basis.
The current mainstay of treatment for PCa is known as androgen deprivation therapy
(ADT), which has proven to be an effective short-term option in earlier stages of the
disease. Unfortunately, longer periods of ADT risk accelerating progression of the cancer
to the point where 25% of all treated patients relapse to an incurable, metastatic, and
highly lethal form known as castration-resistant prostate cancer (CRPC). In
approximately 60% of CRPC cases, a splice variant of androgen receptor called AR-V7
can be detected and has been shown to contribute to this progression.
Recent studies have shown that resveratrol (RSV) is capable of increasing the
polyubiquitination and subsequent proteasomal degradation of ARV7 proteins in CRPC
cells, though the mechanism behind this effect remains unknown. To investigate the
hypothesis that this may occur via downregulation of DBC1 proteins which normally
blocks the polyubiquitination site on AR-V7, 22RV1 cells were cultured and treated with
varying concentrations of RSV for up to 24 hours. Results showed that RSV posttranscriptionally downregulates levels of DBC1 while reducing levels of AR-V7 proteins
and the expression of its target genes. N-cadherin, a known target gene of AR-V7, was
also shown to be downregulated by RSV in a statistically significant and dose-dependent
manner at the mRNA and protein levels. RSV was shown to simultaneously increase
levels of E-cadherin proteins and mRNA in a statistically significant and dose-dependent
manner, suggesting it may be capable of inhibiting or preventing the epithelial-to-
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mesenchymal transition (EMT) in CRPC cells. Together, these findings implicate RSV as
a promising therapeutic option for the majority of CRPC patients who are ARV7positive.
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INTRODUCTION
1.1 Background: prostate cancer diagnosis & treatment
Prostate cancer (PCa) is an incredibly common disease in the United States, with
approximately 170,000 new diagnoses and 30,000 deaths occurring on an annual basis.1
As the second most common cancer in males, 1 out of every 9 American men will be
diagnosed with prostate cancer at some point in their lives and 1 in 41 will die from the
disease.1
Although the overall rate of prostate cancer in the US is declining, the steady rise
in number of diagnoses each year is largely the result of increasing population and
improved diagnostic techniques which allow for earlier detection of the disease before
symptoms arise.2 The most common and widely utilized of these techniques is the
prostate-specific antigen (PSA) assay. However, earlier detection has not reduced the
number of deaths from the disease.2,3 Though there are a number of factors such as age
and growth rate that can influence which treatment options are available to patients, one
of the primary determinants is the stage of the cancer at diagnosis (Figure 1).4
In the early preclinical stages of prostate cancer, an effective first option for many
is watchful waiting, during which a physician will temporarily forgo treatment and
closely monitors the cancer’s progression until it is deemed necessary to pursue more
aggressive treatments such as surgery or radiotherapy. In some cases of PCa, the cancer
can progress so slowly that the patient will never experience any symptoms, and they can
forgo treatment altogether. For the remainder of cases, however, the varying risk of
permanent side effects such as urinary incontinence or impotence—which largely depend
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upon the skill of the surgeon—make these more aggressive options less than ideal.1,4
While the tumor is still confined to the interior of the prostate, radical prostatectomy—a
procedure which involves complete removal of the gland and surrounding tissue—is the
most effective curative treatment available, though hormone therapies remain the primary
treatment option for prostate cancer (Figure 1).

Figure 1.

Standard treatment options by stage in prostate cancer (PCa).

Hormone therapy or androgen deprivation therapy (ADT) is often an effective
short-term option for many with early stage PCa, however prolonged treatment has
shown no association with improved patient outcome and in some cases has even been
found to accelerate progression of the cancer.5 As it stands, around 25% of PCa patients
treated with ADT relapse within 3 years to a much more advanced, aggressive, and
metastatic form known as castration-resistant prostate cancer (CRPC).6,7 There are
currently no reliable curative treatments for prostate cancer once it becomes castrationresistant and what limited therapeutic options remain such as chemotherapy and
immunotherapy have only proven effective at prolonging life by a few months.8 Clearly,
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there is a demand for new and better therapeutic options for patients diagnosed with
progressive forms of prostate cancer and CRPC.
1.2 Mechanisms of PCa progression & Androgen Deprivation Therapy
Androgen & androgen receptors (AR) play a key role in the growth and
maintenance of a healthy prostate, but they can also be among the primary culprits behind
the development and progression of prostate cancer. The androgen receptor (AR-FL) is a
protein in prostate cells comprised of three primary functional domains (Figure 2). At the
N-terminal is a transactivation domain (NTD) which facilitates regulation of canonical
AR target genes responsible for cell maintenance, proliferation, and survival.6,9 Adjacent
to the NTD is the receptor’s primary DNA-binding domain (DBD), followed by a hinge
region which allows homodimerization to other AR when activated.9 Finally, the ligandbinding domain (LBD) at the C-terminus contains the binding site for androgens and will
keep the receptor in an inactive state unless the androgen is bound.9

Figure 2.
Protein structures and functional domains of AR-FL and AR-V7.
In both the full-length androgen receptor (AR-FL) and AR-V7, functional domains include the nterminal domain (NTD) responsible for transcriptional activity and DNA-binding domain (DBD)
facilitating DNA-protein binding to androgen response elements (AREs). AR-FL contains a hinge
region to facilitate homodimerization to AR and a ligand binding domain (LBD) which house the
androgen binding site. In AR-V7, both the hinge region and LBD are missing, resulting in
androgen-independence.
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In healthy prostate tissue, androgen hormones such as testosterone that are
synthesized in the testes and adrenal glands will enter cells where they are then converted
into a more potent form known as 5α-dihydrotestosterone (DHT). The androgens or DHT
can then bind to inactive AR located within the cytoplasm (Figure 3a).5 Binding of the
androgen ligand to AR serves as its activation signal, mobilizing the receptor to dimerize
with another activated AR to form the homodimer which can then translocate to the
nucleus.5 Once there, the DBD binds to specific DNA sequences known as androgen
response elements (AREs) located within the enhancer/promoter regions of canonical AR
target genes.5,10 The NTD then recruits various transcription factors and alters the
expression of those genes.5
One protein produced and secreted by this signaling pathway is prostate-specific
antigen (PSA). In the development of PCa, gradual overactivation of AR causes
dysregulated growth of cells within the prostate and also increases the expression of
PSA.5,9 Increased levels of PSA in the bloodstream is one of the primary markers for
prostate cancer. If left to progress, this can result in tumorigenesis and eventually spread
to other parts of the body. Amplification and/or mutations in the AR gene,
overexpression of coactivators, and alternative splicing are all mechanisms by which this
gradual AR overactivation can occur.11
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In general, treatment with androgen deprivation/hormone therapy targets AR and
deprives the androgen hormone serving as its activation signal.6,10 Enzalutamide and
Abiraterone, two of the major drugs used in ADT, function by blocking the hormone
binding site on AR itself or by inhibiting the body’s ability to synthesize androgens,
respectively (Figure 3b).5

Figure 3.
Androgen/AR signaling in prostate cancer and mechanisms of androgen
deprivation therapy (taken from Nelson et al.).5
Androgen hormone in prostate cancer cells binds over-activated androgen receptors (AR) causing
homodimerization and translocation to the nucleus. Activated nuclear AR homodimers regulate
transcriptional activity of the cells, facilitating a dysregulated increase in proliferation, survival,
and secretion of prostate-specific antigen (PSA)(A). Androgen deprivation therapy (ADT)
restricts cancer cell response to AR overactivation by inhibiting androgen-AR interaction.
Enzalutamide and Abiraterone are two major drugs used in ADT which function via competitive
inhibition at the androgen binding site or inhibition of the body’s de novo synthesis of androgen
hormone, respectively (B).
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Eventual progression of prostate cancer most often occurs via upregulation of AR
splice variants less dependent on androgen as the body tries to adapt to the stresses
imposed by prolonged androgen deprivation.5 By far the most prevalent of these
variations, detected in over 60% of CRPC diagnoses, is known as AR-V7.7 This mutation
generates a truncated but constitutively-active form of the AR that completely lacks the
ligand binding domain, allowing it to function without dependence on the androgen
hormones targeted by ADT (Figure 2).12
Expression of AR-V7 within PCa tissues can be detected by core needle biopsy of
the prostate, and has been associated with decreased survival, shorter progression time to
CRPC, and higher rate of recurrence even after radical prostatectomy.1,7 Overexpression
of AR-V7 has also shown to be strongly associated with older age (>70 y/o) at diagnosis
meaning that, like prostate cancer, age is a prominent risk factor.13 One reason for this
may be the gradual decline in testosterone synthesis that typically occurs as men age,
given that physiological androgen levels show an inverse correlation with AR-V7
expression.14 Seeing as AR-V7 is detected in a majority of CRPC cases7, this would be
consistent with other studies which have shown that patients with CRPC who exhibit
higher (>5 ng/dl) serum androgen levels are significantly more likely to benefit from
ADT than those with lower (<5 ng/dl) levels of androgen.15
1.3 Survey of current research and study aims
Recently, a critical coactivator for AR-V7 in CRPC cell lines was identified as
deleted in breast cancer (DBC1), an AR-FL cofactor which preferentially associates with
AR-V7 and enables it to perform a wide variety of its functions commonly-linked to
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CRPC progression and metastasis.6 One such function specific to AR-V7 is the selective
recruitment to and increased DNA binding affinity for the CDH2 enhancer region upon
association with DBC1 (Figure 4). Once AR-V7 binds the enhancer, the associated DBC1
portion undergoes a conformational change and interacts with the CDH2 promoter region
~20 kb upstream to form a chromatin loop. From this structure, DBC1 facilitates
numerous long-distance chromatin interactions which enable and upregulate transcription
of CDH2.6
The CDH2 gene encodes the N-cadherin protein that is well-established as one of
two primary drivers of the Epithelial-to-Mesenchymal Transition (EMT).6,16 This
mesenchymal marker of EMT is commonly upregulated in CRPC and other metastatic
cancers.6 Cancer cells which undergo this transition exhibit increased migratory capacity,
invasiveness, and a heightened resistance to apoptosis.17 In prostate cancer specifically,
the increase in expression of N-cadherin is considered to be one of the major causes of
progression to metastasis and the development of castration-resistance in CRPC.6,16,18
Once the transitioned cancer cells have adopted the more mesenchymal phenotype, they
can more readily detach from the primary tumor and spread throughout the body.
Eventually, they revert to the more adhesive epithelial phenotype through what is known
as the mesenchymal-to-epithelial transition (MET) and attach themselves at peripheral
sites, where they can begin proliferating to form the secondary tumor.
Although the role of androgens in regulating N-cadherin is not yet known, lower
testosterone levels and therapeutic treatment with androgen deprivation has been strongly
associated with its upregulation.18 In addition to this, N-cadherin/CDH2 expression
during the epithelial-to-mesenchymal transition is reciprocally paired to that of CDH1—a
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gene which encodes E-cadherin, the other major driver of EMT and the primary cell-cell
adhesion molecule in epithelial cells.17 Although the upregulation of N-cadherin is still
required, downregulation of E-cadherin must also occur before EMT can initiate.19
Like CDH2/N-cadherin, another target gene which is shown to be upregulated by
AR-V7, but not the full-length AR, is the ubiquitin-conjugating enzyme E2C
(UBE2C).20,21 This enzyme within the ubiquitin-proteasome pathway functions by
initiating the polyubiquitination and degradation of anaphase-promoting
complex/cyclosome (APC/C) substrates which are crucial to proper chromosome
segregation and the progression of mitosis.22,23 As of 2019, overexpression of UBE2C has
been detected in over 27 different forms of cancer.23 In PCa specifically, increased
expression of UBE2C is directly correlated with increased AR-V7 expression, and has
been associated with shorter overall survival (OS) times, poorer clinical outcomes, and
can indicate tumor progression.21,23 For this reason, it has become a firmly established
therapeutic target in the treatment of many different cancers and diseases.23
An additional function of DBC1 is increasing the stability of AR-V7 by
occupying the same binding site used by the E3 ubiquitin ligase known as C-terminus of
Hsc70-interacting protein (CHIP). In this way, DBC1 effectively competes with the only
enzyme currently known to polyubiquitinate AR-V7 and subsequently target it for
proteasomal degradation (Figure 4).6 Given the enormous prevalence of PCa among men
and the relative lack of long-term treatment options for those with CRPC, any methods
which can combat the underlying causes of CRPC progression such as AR-V7 or DBC1
are well worth pursuing.
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Figure 4.
Schematic showing competitive binding of DBC1 to AR-V7.
Formation of DBC1-ARV7 protein complex leads to increased protein stability and DNA-binding
affinity for AR-V7 target genes (ex. CDH2) associated with increased metastatic potential. Bound
DBC1 competitively blocks the binding site for an E3 ubiquitin ligase known as C-terminus of
Hsc70-interacting protein (CHIP), preventing polyubiquitination and subsequent proteasome
degradation. Created using Figure 6j from Jin Moon et al.6

Resveratrol (RSV, trans-3,4,5-trihydroxystilbene) is one such factor investigated for
its chemopreventative effects in a wide array of cancers, including PCa.24 RSV is a
polyphenolic phytoalexin—a compound released by certain plants when under duress—
that is most commonly found in red grape skins, blueberries, and even peanuts.24 In a
recent study, RSV was found to reduce levels of endogenous AR-V7 proteins and the
corresponding expression of its target genes without affecting levels of the full-length AR
in several different ARV7-positive CRPC cell lines.20 RSV was shown to mediate this
downregulation in a dose-dependent manner by enhancing the polyubiquitination and
subsequent proteasomal degradation of AR-V7 proteins.20 The specific nature of the
mechanism(s) by which RSV mediates this effect on AR-V7 has yet to be determined.
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Given this, and the lack of knowledge regarding the effects of resveratrol on
DBC1, I hypothesize that RSV increases polyubiquitination and degradation of AR-V7
by affecting relative levels of CHIP ubiquitin ligase and/or DBC1, which competes with
it for binding to AR-V7.25 If this is determined to be the case, then treatment with
resveratrol may also function as a mechanism for decreasing the levels of CDH2/Ncadherin in PCa cells, given that it requires DBC1 for its expression.6
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MATERIALS & METHODS

Reagents
RPMI (1X) with L-glutamine culture media was purchased from Corning Cellgro and
stored at 4oC. Premium Fetal Bovine Serum (FBS) was purchased from Atlanta
Biological (Oakwood, GA) and stored at -20oC. Antibiotic-Antimycotic (100X) was
purchased from Life Technologies and stored at 4oC. Dulbecco’s phosphate-buffered
saline (DPBS) was purchased from Gibco Life Technologies (w/o CaCl/MgCl). Trypsin
(0.25%) was purchased from Corning Cellgro and stored at -20oC (without bicarbonate,
0.1% EDTA in HBSS). Resveratrol (RSV) was purchased from Sigma-Aldrich and stored
in the dark at -30oC. 200mM stock solutions of RSV were prepared by dissolving
resveratrol in 100% EtOH (Biotechnology Grade Anhydrous-Alcohol, IBI Scientific,
Peosta, IA). Both the cycloheximide (CHX) solution, and rabbit anti-CHIP antibodies
were purchased from Sigma-Aldrich and stored in the dark at -20oC.
From Invitrogen, 0.1M DTT and First-strand buffer (5X) were purchased and stored
at -20oC. Both Random 9-mer primers purchased from Agilent Technologies and ROX
Reference Dye II purchased from Takara were stored at -20oC. 10 mM dNTP mix and
TaqMan qPCR primers for CCAR2, CDH1, CDH2, UBE2C, KLK3, and GAPDH were
purchased from Thermo-Fisher Scientific and stored at -20oC.
From Bio-Rad Laboratories, Tris/Glycine/SDS Electrophoresis Buffer (10X),
Precision Plus WesternC Protein Standards (stored at -20oC), Precision Protein
StrepTactin-HRP Conjugate (stored at 4oC), Clarity and Clarity Max Western ECL
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substrates were purchased. Ponceau S Total Protein Stain was purchased from Boston
Bio Products. DBC1, ARV7, N-Cadherin, E-Cadherin, and GAPDH antibodies were all
purchased from Abcam and stored at -20oC.
Cell Culture
22RV1 cells obtained from ATCC Bioproducts were cultured in RPMI 1640 1X
with L-glutamine (Corning), 10% premium FBS (Atlanta Biological), and 1% AntibioticAntimycotic (Thermo-Fisher Scientific). Cells were grown in either 10 cm culture dishes
(CellTreat) with 10 mL of growth media or 6-well culture plates (CellTreat) with 2 mL of
growth media replaced every 1-2 days. Cells were kept in incubators at 37oC and 5%
CO2, washed briefly with 1X DPBS (Gibco), and passaged at approximately 70-90%
confluence with 0.25 % trypsin (Corning). Cells were counted using a Countess II digital
cell counter purchased from Life Technologies. Countess cell-counting chamber slides
and Trypan Blue stain were purchased from Invitrogen.
Cell Treatment
At approximate cell counts of 1 million and 5 million cells, 22RV1 cells were
incubated at 37oC and allowed to adhere to 10 cm cell culture dishes or 6-well culture
plates, respectively, for 24 hours prior to treatment. Preparation of resveratrol treatments
was carried out through serial dilution of 200 mM RSV stock solution to 25 µM, 50 µM,
75 µM, and 100 µM in 1X RPMI 1640 growth media (Corning). Preparation of
cycloheximide (CHX) treatments was carried out through serial dilution of 100 mg/mL
ready-made cycloheximide solution (Sigma Aldrich, SKU ID# C4859) to 50 nM and 50
µM in 1X RPMI 1640 growth media. Cells were treated for up to 24 hours. Following
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treatment, all cells were scraped, collected, and pelleted by centrifuge at 3000 RPM and
1000 RPM. Excess media was aspirated and cell pellets were stored at -30oC prior to
RNA purification or preparation of whole cell lysates.
Total RNA Purification
RNA from harvested cell pellets was purified using RNeasy Plus Micro
Purification Kit (Qiagen) in accordance with manufacturer protocol. RNeasy columns
(Qiagen) were used to extract RNA with two elutions of RNase-free H2O (Qiagen)
followed by a 1-minute spin at 15,000 RPM after each elution. Total RNA quantification
was performed using a NanoDrop 2000c UV-Vis Spectrophotometer purchased from
Thermo-Fisher Scientific and samples were stored in the dark at -30oC.
Reverse Transcription-PCR
Before cDNA generation, 10 mM dNTPs (Thermo-Fisher Scientific), random-9mer primers (Agilent), and RNase-free water (Qiagen) were added to 5 µg of sample
RNA and incubated in a Techne thermal cycler for 5 minutes at 65oC. Superscript II
Reverse Transcriptase Kit (Invitrogen) was then used to generate cDNA in accordance
with manufacturer protocol. PCR reactions were carried out in a 3Prime Techne thermal
cycler using the following run method: primer annealing (10 minutes at 25oC), primer
extension (50 minutes at 42oC), and primer inactivation (15 minutes at 70oC.) 76 µL of
nuclease-free H20 (Thermo-Fischer) was added to the resulting cDNA samples which
were then stored at -20oC.
Quantitative Real-Time PCR
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qPCR reactions were carried out using TaqMan Universal PCR kit (Applied Biosystems).
in accordance with manufacturer’s protocols. The master mixes were made using [] µg
cDNA, RNase-free H2O (Qiagen), TaqMan qPCR premix, ROX II Reference Dye
(Thermo-Fisher Scientific), and appropriate qPCR probes. From Thermo-Fisher
Scientific, target primers were purchased for CCAR2/DBC1(human, Primer ID#
Hs00377763_CE), CDH1/E-cadherin (human, Primer ID# Hs00345541_CE), CDH2/Ncadherin(human, Primer ID# Hs00174449_CE), and UBE2C(human, Primer ID#
Hs00215129_CE) alone or in multiplex with GAPDH(human, Catalog ID# 402869), the
housekeeping gene used as an endogenous control. 25 µL of master mix was loaded in
triplicate or quadruplicate into each well of a 96-well qPCR reaction plate (Applied
Biosystems), capped with 8-strip tube caps (Applied Biosystems), centrifuged for 30
seconds, and analyzed using the StepOne Plus Real-Time PCR System (Applied
Biosystems) with the following run method over 40 cycles: hot start (30 seconds at
95oC), denature (5 seconds at 95oC), and extension (37 seconds at 60oC).
Whole Cell Lysate Preparation & Quantification
Harvested cells were resuspended in either 50 or 100 µL of
radioimmunoprecipitation assay (RIPA) lysis buffer depending on pellet size, vortexed,
and left on ice for 15 minutes to lyse. Following lysis, samples were kept at 4oC and
centrifuged for 30 minutes at 15,000 RPM. The supernatant lysates were then transferred
to new sample tubes and stored at -30 oC while remaining cellular debris was discarded.
Pierce BCA Protein Assay Kit purchased from Thermo-Fisher Scientific was used in
accordance with manufacturer’s protocols to determine total protein concentration of
each lysate.
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Protein Gel Electrophoresis & Western Blot
Protein samples were prepared using 25-50 µg of total protein, reagent-grade
double distilled (RGDD) water, and sodium dodecyl sulfate (SDS) loading buffer.
Samples were denatured at 95oC for 5 minutes, then separated by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) (5% stacking, 10% separating) running at 125mV for 2
hours. Following separation, bands were transferred to mini nitrocellulose membranes
purchased from Biorad using iBlot gel transfer stacks (Thermo-Fisher Scientific) in
accordance with manufacturer protocols. Successful band transfer was verified using
Ponceau S total protein stain (Boston Bio Products), which was removed by washing in
1X TBS for 10 minutes.
Membranes were blocked with Fast Western AB Diluent (Thermo-Fisher
Scientific) for 1 hour, washed twice with 1X TBS-Tween (0.1%) for 10 minutes each,
and incubated overnight in primary antibody dilution at 4oC. Antibodies against ARV7
(rabbit recombinant monoclonal, ID# ab198394) , DBC1 (rabbit monoclonal, ID#
ab128890), E-cadherin (mouse monoclonal, ID# ab1416), and N-cadherin (rabbit
polyclonal, ID# ab76057) were purchased from Abcam and used at 1:1000 dilution, while
CHIP (rabbit polyclonal, ID# C9243) was purchased from Sigma-Aldrich and was used
at 1:5000 dilution. Antibody against GAPDH (rabbit recombinant monoclonal, ID#
ab181602) was also purchased from Abcam and was used as a loading control at a 1:1000
dilution. Membranes were then washed 3x for 10 mins in TBS-T(1X), incubated in
secondary antibody conjugated to HRP (Biorad) for 15 minutes at 4oC, washed another
3x for 10 mins in TBS-T(1X), and given a final 10 min wash in TBS(1X). Pierce Fast
Western Blot ECL Substrate (stored at 4oC) and Fast Western Optimized HRP Reagent
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were purchased from Thermo-Fisher Scientific. Clarity Max Western ECL kit solutions
purchased from Biorad were then introduced in a 1:1 mixture to visualize protein bands
using a Biorad ChemiDoc MP Imager. Band intensities were quantified and normalized
to GAPDH using ImageLab software according to manufacturer protocols (Biorad).
Statistical Analysis
SPSS software purchased from IBM was used for statistical analysis of relative
quantification (RQ) values in all qPCR experiments. Significant difference among all
treatment groups was first determined using one-way ANOVA with an alpha of 0.05.
Following statistically significant one-way ANOVA, differences between individual
sample groups were then determined using post-hoc Tukey HSD multiple comparisons
analysis.
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RESULTS

1.1 The effects of resveratrol on the mRNA levels of DBC1
In a previous study, RSV was found to be able to reduce AR-V7 transcriptional
activity and the expression of its target genes without impacting levels of AR-V7
mRNA.20 As a target gene of AR-V7 but not the full-length AR, expression of UBE2C
has also shown to be reduced at both the mRNA and protein levels upon treatment with
RSV.20,21 What is not yet known is whether DBC1 also exhibits this downregulation
under the same conditions and, if so, whether that decrease might play a role in RSVmediated AR-V7 degradation.
In order to investigate the effects of RSV on DBC1 mRNA, 22RV1 cells
expressing high levels of AR-V7 and low levels of AR-FL20 were cultured and treated
with or without 25-100µM of RSV for a period of 24 hours. qPCR was performed using
ΔΔCT method to measure the relative quantification (RQ) of DBC1 mRNA as the target
gene, UBE2C as a positive control, and GAPDH as an internal control.
As seen in figure 5a, UBE2C mRNA levels showed little to no change at 25 µM
RSV when compared to the untreated sample but exhibited statistically significant and
dose-dependent decreases when treated with concentrations of 50 µM, 75 µM, and 100
µM RSV. This decrease was expected and is consistent with results obtained by Wilson
et al.20 Additionally, this downregulation is consistent with the previously established
RSV-mediated decrease in AR-V7 and its transcriptional activity, suggesting that this
effect had successfully been replicated in my experiment.20 Under the same conditions,
however, mRNA levels of DBC1 exhibited no statistically significant difference across
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the four concentrations of RSV when compared to the untreated sample (Figure 5b). This
suggests that RSV does not affect DBC1 mRNA levels.

Figure 5.

RSV induces dose-dependent decrease in UBE2C but does not alter mRNA
levels of DBC1.
22RV1 cells were cultured and treated with serial dilution of 25-100µM RSV for 24 hours. qPCR
was performed in quadruplicate with GAPDH as endogenous control in multiplex with the target
genes. Quantities of target mRNAs relative to untreated controls were calculated by ΔΔCT
method and expressed as mean +/- SEM with CT SD <0.1. Graphs show results from three
independent experiments (n = 3). Statistical significance was determined by post-hoc Tukey HSD
multiple comparisons analysis following statistically significant 1-way ANOVA: *, p<0.05; **,
p<0.001. Relative levels of UBE2C mRNA as an established AR-V7 target genes showed
significantly decreased levels at 50, 75, and 100µM RSV (A). Relative levels of DBC1 mRNA
showed no significant difference across all treatment groups (B).
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1.2 Resveratrol down-regulates protein levels of DBC1
Similar to the effects on AR-V7, any resveratrol-mediated downregulation which
may occur in DBC1 does not appear to affect its expression at the mRNA level. In ARV7, however, downregulation was established to occur post-translationally via increased
polyubiquitination and subsequent proteasomal degradation.20 Though the specific
mechanisms behind this effect have yet to be discovered, both the downregulation of
DBC1 and the upregulation of CHIP remain plausible mechanisms for this increase in
AR-V7 polyubiquitination.
To investigate the overall effects of RSV on these two proteins, 22RV1 cells were
cultured and treated with or without 100 µM RSV for up to 24 hours and harvested every
four hours. Treatment at 100 µM was chosen as is it exhibited the greatest
downregulatory effect on UBE2C at the mRNA level (Figure 5a), and findings by Wilson
et al.20 using same cell line previously showed significantly decreased AR-V7 proteins at
this concentration. Successful gel to membrane transfer was verified using Ponceau S
total protein stain as seen in figure 6b, and Western blotting was conducted with
antibodies against DBC1, AR-V7, and CHIP as target proteins (Figure 6a). GAPDH
served as an internal loading control.
As seen in figures 6a and 6c, DBC1 protein bands in the samples treated with
RSV showed a gradual decrease during the first 16 hours post-treatment to around one
third of the intensity of the untreated sample. At 20 hours post-treatment, DBC1 bands
begin to increase again, ultimately reaching an intensity around 86% of the control at 24
hours (Figure 6c). Together with results from the previous experiment, this overall
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decrease in band intensity suggests that treatment with RSV post-transcriptionally
downregulates levels of DBC1.
As seen in figures 6a and 6d, AR-V7 protein bands showed a distinctive increase
in intensity from the control sample to the first treated sample collected at 4 hours posttreatment, suggesting a brief upregulation of AR-V7 proteins upon initial exposure to
RSV. As expected for a positive control and consistent with data obtained in other
studies20, all subsequent samples collected at 8- to 24-hours post-treatment displayed a
gradual decrease in AR-V7 proteins (Figure 6d). After normalization to GAPDH, CHIP
protein bands appeared to remain constant in each of the treated samples when compared
to those in the untreated sample, suggesting that levels of CHIP proteins are additionally
unaffected by RSV (Figures 6e).
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Figure 6.
Effects of RSV on DBC1, AR-V7, and CHIP protein levels over 24 hours.
22RV1 cells were cultured and treated with or without 100µM RSV for up to 24 hours. Cells
were harvested every 4 hours and whole cell lysates were prepared and quantified. 50 µg of total
protein per sample was separated via (5%, 10%) SDS-PAGE and transferred to nitrocellulose
membranes. Western blotting was conducted using antibodies for DBC1, AR-V7, and CHIP with
GAPDH serving as loading control (A). Protein band intensities were normalized and quantified
using ImageLab software. Gel to membrane transfer was verified using Ponceau S total protein
stain (B). A time-course was plotted showing normalized, relative intensities of DBC1 (C), ARV7 (D), and CHIP (E) protein bands averaged from three independent experiments, each
performed in duplicate (n = 3).
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2.1 The effects of resveratrol on DBC1 protein stability
To further investigate the mechanism behind this RSV-induced downregulation of
DBC1 proteins, 22RV1 cells were cultured and treated with 50nM or 50µM
cycloheximide (CHX) alone or in combination with 100 µM RSV. Cells were harvested
at 2-, 4-, 8-, and 12-hours post-treatment, and Western blotting was conducted with
antibodies against DBC1 and AR-V7 as target proteins using GAPDH as a loading
control (Figure 7).
For the cells treated with 50 nM of cycloheximide seen in figures 7a and 7b,
DBC1 protein bands increased in intensity during the first 4 hours post-treatment to
approximately 5-times and 3-times the levels seen in the untreated sample for the “CHX
+ RSV” and “CHX only” groups, respectively. Over the next 8 hours these same groups
began to steadily decrease, ultimately reaching levels just above those found in the
untreated sample by 12-hours post-treatment (Figure 7b). As seen in figure 7c, the ARV7
protein bands followed a similar trend to DBC1 in both groups, reaching levels about
twice those seen in the untreated sample by 12-hours post-treatment.
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Figure 7.

50 nM cycloheximide chase analysis showing effects of RSV on DBC1 & ARV7
protein degradation.
22RV1 cells were cultured and treated with 50 nM CHX alone or in combination with 100µM
RSV. Cells were incubated for up to 12 hours and harvested at 2-, 4-, 8-, and 12-hours posttreatment. Whole cell lysates were prepared and quantified using ImageLab. 30 µg of total
protein per sample was separated via (5%, 10%) SDS-PAGE and transferred to nitrocellulose
membranes. Western blotting was conducted using antibodies for DBC1 and AR-V7 with
GAPDH used as loading control (A). Relative protein band intensities were normalized and
quantified using ImageLab software. Band intensities for both DBC1 (B) and AR-V7 (C) proteins
were averaged between three independent experiments, each performed in duplicate (n = 3), and
plotted as a time-course.

When treated with the higher 50 µM concentration of CHX detailed below in
figures 8a and 8b, DBC1 proteins in the “CHX only” group showed an immediate
decrease to ~60% of the control sample at 2-hours post-treatment. The levels then
increased to well above those in the control sample at 4-hours and gradually began
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decreasing to ~45% by 12-hours post-treatment. In the group treated with both CHX and
RSV, the levels of DBC1 remained relatively unchanged across all 12 hours, the
exception being the sample at 4-hours post-treatment which, again, increased to above the
levels in the control.
As seen in figure 8c, levels of AR-V7 proteins in both the “CHX only” and “CHX +
RSV” groups remained relatively identical to each other at each time interval. As a
positive control, this trend is inconsistent with findings obtained under identical
experimental parameters by Wilson et al.20, who reported increased AR-V7 degradation
in samples treated with RSV. At 8-hours post-treatment, protein levels of AR-V7 in both
groups began to decrease steadily, reaching approximately 50% of basal levels by hour
12. Given the inconsistencies to reported findings in other studies and the lack of a viable
positive control, only two experiments were run at 50 µM CHX and protein stability
results at both concentrations were inconclusive.
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Figure 8.

50 µM cycloheximide chase analysis showing effects of RSV on DBC1 & ARV7
protein degradation.
22RV1 cells were cultured and treated with 50 µM CHX alone or in combination with 100µM
RSV. Cells were incubated for up to 12 hours and harvested at 2-, 4-, 8-, and 12-hours posttreatment. Whole cell lysates were prepared and quantified using ImageLab. 30 µg of total
protein per sample was separated via (5%, 10%) SDS-PAGE and transferred to nitrocellulose
membranes. Western blotting was conducted using antibodies for DBC1 and AR-V7 with
GAPDH used as loading control. (A). Relative protein band intensities were normalized and
quantified using ImageLab software. Band intensities for both DBC1 (B) and AR-V7 (C) proteins
were averaged between two independent experiments (n = 2) and plotted as a time-course.

3.1 The effects of resveratrol on the mRNA levels of CDH1 and CDH2
In a recent study, it was shown that DBC1 acts as an essential coactivator required
for the expression of many ARV7-specific target genes including CDH2.6 In addition to
this, CDH2 or N-cadherin expression during the epithelial-to-mesenchymal transition
(EMT) is reciprocally paired to that of CDH1—a gene which encodes the primary cell-
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cell adhesion molecule in epithelial cells known as E-cadherin—though the specific
mechanisms behind this link have yet to be discovered.17 Although my previous findings
have shown that RSV downregulates protein levels of DBC1, it has not been determined
whether RSV has any effect on the expression of N-cadherin in prostate cancer cells and
if such an effect would be reflected in E-cadherin expression.
In order to investigate the effects of RSV on the mRNA levels of CDH1 and
CDH2, 22RV1 cells were again cultured and treated with or without 25-100µM serial
dilutions of RSV for a period of 24 hours. qPCR was performed and the housekeeping
gene GAPDH was multiplexed with the TaqMan probes for the genes of interest to
normalize mRNA expression (Figure 9). As seen in figure 9a, mRNA levels of CDH2
exhibited a statistically significant and dose-dependent decrease at 25, 50, 75, and 100
µM RSV when compared to those in the untreated sample (p < 0.01). This indicates that
treatment with RSV downregulates expression of CDH2 at the mRNA level.
Under the same conditions seen in figure 9b, mRNA levels of CDH1 followed a
reciprocal trend to that of CDH2, exhibiting a dose-dependent increase with increasing
concentrations of RSV. Unlike CDH2, however, mRNA levels of CDH1 were only
shown to be significantly different from the untreated sample at concentrations of 50, 75,
and 100 µM RSV. This suggests RSV is capable of regulating both CDH1 and CDH2
mRNA levels. Additionally, morphological changes in the cells could be observed at
RSV concentrations of 50 µM and higher. With increasing concentration, the number of
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cellular extensions and overall size of the cells showed a marked decrease, while overall
cytoplasmic granularity, cell detachment, and cell death appeared to an increasing degree.

Figure 9.
Effect of increasing concentrations of RSV on CDH1 & CDH2 mRNA levels.
22RV1 cells were cultured and treated with serial dilution of 25-100µM RSV for 24 hours. qPCR
was performed in quadruplicate with GAPDH as endogenous control in multiplex with the target
genes. Quantities of target mRNAs relative to untreated controls were calculated by ΔΔCT
method and expressed as mean +/- SEM with CT SD <0.1. Graphs show results from three
independent experiments (n = 3). Statistical significance was determined by post-hoc Tukey HSD
multiple comparisons analysis following statistically significant 1-way ANOVA: *, p<0.01; **,
p<0.001. Relative levels of CDH2 mRNA showing significant decreases in all treatment groups
when compared with the control group (A). Relative levels of CDH1 mRNA as showing
significantly increased levels at 50, 75, and 100µM RSV (B).
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3.2 RSV effects on EMT-associated E- & N-cadherin proteins
In order to investigate whether the effects of RSV on CDH2 and CDH1 mRNA
are reflected at the protein level, 22RV1 cells were again treated with or without 100 µM
RSV for up to 24 hours and harvested every four hours. Successful gel to membrane
transfer was verified using Ponceau S total protein stain seen in figure 10b, and Western
blotting was conducted with antibodies against both N-cadherin and E-cadherin, using
GAPDH as a loading control.
As seen in figures 10a and 10c, N-cadherin protein levels remained relatively
unchanged during the first 12 hours post-treatment with RSV. Consistent with the
previously observed downregulation of CDH2 mRNA levels, protein levels of Ncadherin at 16- and 20-hours post treatment showed a gradual decline with approximately
50% decrease in intensity by 24 hours when compared to the untreated sample (Figure
10c). This indicates that treatment with RSV downregulates N-cadherin at the both the
protein and mRNA levels.
Also consistent with previous results showing upregulation at the mRNA level,
protein levels of E-cadherin exhibited a marked increase at 4-hours post-treatment and
continued to increase to approximately 2.5 times the basal levels at hour 16 (Figure 10d).
By 20-hours post-treatment, protein levels begin to decrease again, though they remain
approximately 1.5 times basal levels by hour 24. This indicates RSV upregulates Ecadherin at both the mRNA and protein levels while downregulating levels of N-cadherin
mRNA and proteins. As observed in the previous experiment, a dramatic change in cell
morphology also began to occur with increasing incubation periods in the treatment
media. Slight cytoplasmic granulation and reduction in size appeared to begin at around

34
8-hours post-treatment with a marked increase in plate detachment and cell death
occurring by hour 12.

Figure 10. Effects of RSV on N-cadherin & E-cadherin protein levels over 24 hours.
22RV1 cells were cultured and treated with or without 100µM RSV for up to 24 hours. Cells
were harvested every 4 hours and whole cell lysates were prepared and quantified. Protein band
intensity was averaged from 3 independent experiments (n = 3). 50 µg of total protein per sample
was separated via SDS-PAGE and transferred to nitrocellulose membranes. Western blotting was
conducted using antibodies for N-cadherin and E-cadherin with GAPDH serving as loading
control (A). Gel to membrane transfer was verified using Ponceau S total protein stain (B). A
time-course was plotted showing normalized, relative intensities of N-cadherin (C) and Ecadherin (D) protein bands averaged from three independent experiments, each performed in
duplicate (n = 3).
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DISCUSSION
As of 2019, there are still no reliable curative treatments available for patients
diagnosed with CRPC.1 In over 90% of cases, development of castration-resistance in
prostate cancer is accompanied by a shift to a more aggressive and metastatic cancer cell
behavior which is highly lethal and quickly spreads to other areas of the body.12 The most
common cause of progression to CRPC detected in over 60% of cases is upregulation of
AR-V7, which does not respond to any form of hormone therapy currently used and has
been associated with decreased patient survival and shorter progression time to
CRPC.7,12,26 Clearly for the many patients who are ARV7-positive and those with CRPC,
there is an urgent need for novel treatment options which do not rely upon androgen
deprivation and can specifically target AR-V7.
One such compound with the potential to target AR-V7 is resveratrol, which was
previously shown to reduce AR-V7 protein levels in prostate cancer cells by enhancing
its polyubiquitination and subsequent proteasomal degradation.20 Within this study, I
explored potential mechanisms for this increased polyubiquitination of ARV7 by RSV.
Specifically, my investigation focused on CHIP and DBC1, as well as E- and Ncadherins given that they have been implicated in recent studies to play a role in the
degradation of AR-V7 and the epithelial-to-mesenchymal transition, respectively.6,16
Given the lack of knowledge regarding the effect of resveratrol on DBC1, I
hypothesized that RSV may increase polyubiquitination and degradation of AR-V7 by
affecting relative levels of CHIP ubiquitin ligase and/or DBC1, which competes with it
for binding to AR-V7.25 Following from this, I also hypothesized that treatment with

36
RSV would decrease levels of CDH2/N-cadherin in PCa cells, given that it is a target
gene of AR-V7 and requires DBC1 for its expression.6 Furthermore, the fact that
CDH1/E-cadherin expression is inversely tied to that of N-cadherin during EMT lead me
to surmise that E-cadherin levels should also increase as a result of resveratrol
treatment.17
Any potential findings which could be linked to regulation of EMT in PCa are
particularly worthy of investigating, as this process has proven to be crucial to cancer cell
metastasis and progression to CRPC.16 So as to establish cellular conditions in vitro
which closely approximate most clinical cases of CRPC, my research was conducted
using 22RV1 cells—a cell line comprised of human CRPC cells which endogenously
express both high levels of AR-V7 and low levels of AR-FL.27
In order to determine whether treatment with resveratrol affects the expression of
DBC1, I first looked for potential regulation occurring at the mRNA level. To this end,
22RV1 cells were treated with serial dilutions of RSV ranging from 0 – 100 µM and
incubated for a period of 24 hours. For UBE2C, a target gene of AR-V7 and not AR-FL21
acting as the positive control, (Figure 5a) results showed a statistically-significant and
dose-dependent reduction in mRNA levels with increasing RSV concentration. This was
consistent with findings made in another study and suggests that the RSV-mediated
decrease of ARV7 proteins had been replicated in my experiment.20 As mentioned
previously, UBE2C is commonly dysregulated to increased levels in the advanced stages
of over 27 different forms of cancer.21,23 In PCa, increased expression of UBE2C is
directly correlated with increased AR-V7 expression21 and has been associated with
shorter overall survival (OS) times, poorer clinical outcomes, and can indicate tumor
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progression.23 The reduction in UBE2C mRNA levels after RSV treatment shown in this
study may provide a relevant avenue for future research as it is a therapeutic target in
many different cancers.23 Results seen in figure 5b showed that under the same
conditions, mRNA levels of DBC1 were unaffected by treatment with RSV. These
findings suggest that the increased polyubiquitination and degradation of AR-V7 induced
by resveratrol are likely not the result of downregulation of DBC1 occurring at the
mRNA level.
Given that CHIP upregulation or DBC1 downregulation could both potentially
result in enhanced polyubiquitination of AR-V7, I investigated the effects of RSV on
protein levels of DBC1, CHIP, and AR-V7 (Figure 6). To this end, 22RV1 cells were
treated with or without 100 µM RSV and collected every 4 hours to monitor incubation
periods for up to 24 hours. Results from western blotting experiments (Figure 6c) showed
that DBC1 protein levels decrease steadily over time with RSV treatment. Somewhat
unexpectedly, DBC1 levels did begin to increase again at 20- and 24-hours post
treatment, though not to baseline levels found in the untreated sample. One potential
explanation for this may be the degradation of resveratrol within the treatment media
after ~20 hours. Growth media used to prepare treatments in this study was kept at
physiological pH of 7.4, and research on the chemical stability of resveratrol under in
vitro conditions has shown that degradation occurs exponentially at pH > 6.8.28 This is
consistent with the fact that the relative decrease in DBC1 protein levels is greatest at 4hours post-treatment and appears to drop off with time. Unfortunately, this relative
instability at physiological pH also demonstrates what is currently one of the major
obstacles to the use of RSV as a potential treatment. Not only is it chemically unstable in
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conditions within the body, but like many phytochemicals, RSV has a very low
bioavailability in human tissues and would require constant administration in high doses
to maintain therapeutic concentrations.29,30 While RSV is rapidly absorbed when
administered orally, it is quickly conjugated and metabolized by the first-pass effect and
only trace amounts of unaltered RSV have been shown to make it into systemic
tissues.29,31 In an effort to combat this problem, a synthetic derivative of RSV known as
pterostilbene (PTS) has been developed which, in several studies, has been shown to
exhibit both higher bioavailability and stronger pharmacological activity than RSV.29,30,32
As expected in the positive control, protein levels of AR-V7 showed a steady
decrease over time with RSV, but only after an initial increase was observed immediately
following treatment (Figure 6d). Aside from this increase, these results were consistent
with those obtained in a separate study which used the same cell line.20 A survey of the
relevant literature revealed no functions or interactions which might explain the initial
upregulation of AR-V7 proteins upon treatment with RSV, however the regulatory
mechanisms which drive the alternative splicing and production of AR-V7 are not
currently well understood. In figure 6e it was also shown that levels of CHIP protein
remain constant in the presence of RSV. Together, these results indicate that RSVmediated downregulation also occurs post-transcriptionally in DBC1, albeit with an
earlier time of onset by a few hours. Concurrently, levels of CHIP protein appeared to be
unaffected by treatment with RSV. This further supports my hypothesis that RSV
increases AR-V7 polyubiquitination via downregulation of DBC1 proteins and not via
upregulation of CHIP. Though all data gathered over the course of my investigation
supported and was consistent with this hypothesis, further research would be required to
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state conclusively that this is the case or that it is the sole mechanism involved. With the
exceedingly wide range of anti-cancer effects attributed to RSV across a variety of
different cancers, it is well within the realm of possibility that more than one of them
could be contributing to the increased polyubiquitination of AR-V7.24,29,31,33-35
One major limitation in my study occurred when attempting to further investigate
the mechanism for RSV-induced downregulation of DBC1 protein. In using
cycloheximide—a potent inhibitor of protein synthesis in eukaryotic cells—to track
protein degradation over time, I was ultimately unable to determine whether RSV has any
effects on DBC1 or AR-V7 protein stability. Results at 50 nM CHX (Figures 7b-c)
showed DBC1 proteins increasing over time and AR-V7 proteins following a similar
trend to DBC1 in both groups, reaching levels about twice those seen in the untreated
sample by 12-hours post-treatment. Because this was inconsistent with results obtained in
previous experiments and seemed to indicate an increase in protein levels following
treatment with a protein synthesis inhibitor, the experiment was deemed inconclusive.
Given that the EC50 for CHX to inhibit protein synthesis can vary depending on cell-type
and the specific conditions in vitro, the experiment was re-attempted at a higher
concentration of CHX. Results at 50 µM CHX (Figures 8b and 8c) showed DBC1
seemingly unaffected over time and levels of AR-V7 in both the “CHX only” and “CHX
+ RSV” groups remaining relatively identical to each other at each time interval. As the
positive control, this trend is inconsistent with findings obtained under identical
experimental parameters in Wilson et al.20, who reported increased AR-V7 degradation in
samples treated with RSV. 20Also inconsistent with that study, which showed a 50%
reduction in AR-V7 by 2-hours post-treatment, AR-V7 levels in my experiment remained
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roughly equal to that of the control sample until hour 8, when they began a gradual
decrease and did not reach ~50% until 12-hours post-treatment.20 Given these
inconsistencies with the literature at both concentrations and the lack of viable positive
control data, only two experiments were run at 50 µM CHX and I was unable to draw any
conclusions regarding the effects of RSV on DBC1 or AR-V7 protein stability. One
potential explanation for these inconsistencies is that RSV somehow interferes with
cycloheximide’s ability to block protein synthesis. In at least one other study, treatment
with RSV in vitro was shown to greatly reduce cycloheximide-induced cell death
resulting from inhibited protein synthesis.36 Another factor which may have contributed
to the inconsistency is the slight overlap of the protein bands on the blot, which made it
difficult to consistently and reliably quantify individual bands.
CDH2 or N-cadherin expression during the epithelial-to-mesenchymal transition
is reciprocally paired to that of CDH1—a gene which encodes the primary cell-cell
adhesion molecule in epithelial cells known as E-cadherin.17,37 Finding potential cancer
treatments which can affect these EMT marker molecules are particularly important
given that, alongside the loss of E-cadherin, increased levels of N-cadherin have shown
to be one of the primary drivers of progression to metastasis and the development of
castration-resistance in PCa.6,16-18 In order to investigate the effects of RSV on mRNA
levels of CDH1 (E-cadherin) and CDH2 (N-cadherin), 22RV1 cells were treated with
serial dilutions of RSV ranging from 0 – 100 µM and incubated for a period of 24 hours.
qPCR results (Figure 9a) showed a statistically significant and dose-dependent decrease
in levels of CDH2 mRNA with increasing concentrations of RSV. This suggests that
RSV downregulates CDH2 expression at the mRNA level. Consistent with this finding
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and the known reciprocal expression patterns of CDH1 and CDH2, results (Figure 9b)
showed that levels of CDH1 mRNA were increased in a statistically significant and dosedependent manner with RSV concentration. This indicates that RSV can both
downregulate levels of CDH2 mRNA and upregulate levels of CDH1 mRNA. Having
previously established a decrease in DBC1 protein levels with RSV treatment, these
findings support my hypothesis that RSV-induced depletion of DBC1 and a resulting
reduction in AR-V7 proteins would lead to decreased levels of N-cadherin. More
importantly, it suggests that RSV is capable of decreasing the expression of N-cadherin
while simultaneously increasing expression of E-cadherin. Given that basal levels of
CDH1 were greater than CDH2 in these cells both before and after treatment, this
indicates that RSV may be inhibiting the cadherin switch that makes up the crucial first
step in the initiation of EMT.17,19,37
In order to determine whether the effects of RSV impact protein levels of N- and
E-cadherin, 22RV1 cells were again treated with or without 100 µM RSV and collected
every 4 hours to monitor incubation periods for up to 24 hours (Figure 10a). Western
blotting results (Figure 10c) showed that protein levels of N-cadherin remain steady until
around 16-hours post-treatment with RSV, at which point they begin to decrease steadily.
This delayed but present reduction in N-cadherin proteins is consistent with the observed
decrease in mRNA levels of CDH2, given the additional time it would take for
transcriptional changes to be reflected at the protein level. Together, this shows that
treatment with RSV can downregulate N-cadherin expression at both the protein and
mRNA levels. This is particularly relevant given that, alongside the loss of E-cadherin,
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increased expression of N-cadherin is one of the primary drivers of metastasis and the
development of castration-resistance in CRPC.16,18
Results (Figure 10d) additionally showed an immediate and marked increase in Ecadherin proteins after only 4 hours of RSV exposure. These levels continued to increase
over the next 12 hours, albeit more gradually, before reaching peak levels at around 16hours post-treatment. This was consistent with the previously shown increase in CDH1
mRNA and indicates that RSV can also upregulate expression of E-cadherin at both the
mRNA and protein levels. The large difference in onset time for this effect when
compared to N-cadherin, however, implies that RSV may mediate its effect(s) on Ecadherin through another mechanism. While an upregulation of E-cadherin at the mRNA
level is present as well, the strength and onset of the protein increase at 4-hours posttreatment (Figure 10d) may imply the existence of additional upregulatory effects which
act on multiple levels. In several other late-stage cancers such as gastric, colorectal, and
lung cancer, numerous studies have shown that RSV is capable of increasing E-cadherin
at both the mRNA and protein level via downregulation of SNAI1, a nuclear transcription
factor which inhibits E-cadherin expression during EMT.33,35 In these studies, it was
reported that this increase in E-cadherin was also accompanied by significant changes in
cell morphology and suppression of the EMT phenotype.33,35 This is consistent with the
morphological changes in the CRPC cells that were observed in my experiment. There
are, however, additional protein markers which characterize EMT that require
investigating to conclude for certain if RSV can affect the process itself.
Similar to the levels of DBC1 protein, E-cadherin proteins also appeared to begin
decreasing between 16- and 20-hours post-treatment, though they remain at increased
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levels when compared to the untreated sample at 24-hours post-treatment. This is
consistent with my hypothesis that RSV treatment reciprocally affects levels of N- and Ecadherin, and supports the likelihood that the increase in DBC1 proteins after ~20 hours
(Figure 6c) is the result of RSV degradation in the growth media.
This effect is nevertheless relevant, as the loss of E-cadherins and epithelial cellto-cell adhesion is what is primarily characterized by the epithelial-to-mesenchymal
transition, and cancer cells that undergo this transition show significantly increased
migratory capacity, invasiveness, and resistance to apoptosis.17,18 Having established that
downregulation of DBC1 proteins does occur with RSV treatment, these findings lend
further support to my hypothesis that RSV-induced depletion of DBC1 and the resulting
reduction in AR-V7 proteins may decrease the expression of N-cadherin and increase the
expression of E-cadherin. As stated previously, this effect holds the potential to be highly
relevant for future studies researching treatment of ARV7-positive CRPC as it suggests
RSV may be able inhibit the cadherin switch during EMT that is required for cancer cells
to gain their metastatic potential. Because the basal levels of E-cadherin still exceeded
those of N-cadherin in the cancer cells in this study, they are still characteristically
epithelial and therefore this effect represents a potential inhibition of EMT rather than
induction of MET. In any case, the importance of developing the kinds treatments which
reduce metastatic potential cannot be overstated as currently over 90% of mortalities
linked to any form of cancer arise due to the metastasis and growth of secondary
tumors.34
Aside from the inconclusive results regarding DBC1 and AR-V7 protein
degradation, one more major limitation/potential source of uncertainty was encountered
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during the course of this study. In performing western blots measuring protein levels of
DBC1, three distinct signal bands at ~88, 70, and 60 kDa were consistently detected on
the membranes when only one is reported in MCF7 cells by the manufacturer of the
primary antibody (Figure 11). There are no currently known isoforms or splice-variants
of DBC1, so only the strongest signal present at the reported molecular weight of 88 kDa
was quantified and reported in this study. Given that the other bands appeared at lower
molecular weights, they could represent artifacts of DBC1 degradation, however this
typically presents as one long smeared band these appear as discrete and separate signals.
Furthermore, degradation product signals would typically reflect the intensity of the
primary band, yet expression trends for these are consistent and distinct from those of the
primary band or the other signal, so I believe this explanation to be unlikely. It is also
possible that they result from overloading the gel with too much protein at 50 µg,
however they were still present when 20 and 30 µg of protein were loaded, so this
explanation is also not very likely. They are detected by other researchers using 22RV1
cells in the same lab and MCF7 cell lysates run in the same gel show only the primary
band, so it is not likely due to personal laboratory technique and may simply be an effect
specific to the 22RV1 cell line.

Figure 11.

Western blot showing triple DBC1 protein bands at 20 and 50µg in 22RV1
cells treated w/ or w/o 100 µM RSV.
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In conclusion, this study has demonstrated in prostate cancer cells that treatment
with resveratrol post-transcriptionally downregulates protein levels of DBC1 while
reducing levels of AR-V7 protein and the subsequent expression of its target genes.
Protein levels of CHIP ligase were unaffected by treatment with RSV, suggesting that it
may mediate enhanced AR-V7 polyubiquitination and proteasomal degradation by
decreasing levels of DBC1. It was demonstrated that RSV treatment causes
downregulation of N-cadherin mRNA and protein levels in a statistically significant and
dose-dependent manner. RSV was also shown to simultaneously increase levels of Ecadherin mRNA and proteins in a statistically significant and dose-dependent manner,
suggesting it may be capable of inhibiting the epithelial-to-mesenchymal transition in
CRPC cells. Together, these findings have indicated that RSV is worthy of further study
as a promising therapeutic option for patients diagnosed with ARV7-positive prostate
cancer and CRPC.
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